Comparison of PD-L1 expression before and after neoadjuvant chemoradiation or chemotherapy in stage III non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Koenig, D. [1 ]
Prince, S. Savic [2 ]
Trachsel, B. [3 ]
Hayoz, S. [3 ]
Pless, M. [4 ]
机构：
[1] Univ Hosp Basel, Med Oncol Dept, Basel, Switzerland
[2] Univ Hosp Basel, Inst Pathol & Med Genet, Pathol Dept, Basel, Switzerland
[3] SAKK, Swiss Grp Clin Canc Res, Bern, Switzerland
[4] KSW Kantonsspital Winterthur, Med Oncol & Tumor Ctr, Winterthur, Switzerland
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5P
引用
收藏
页码：S1376 / S1376
页数：1
相关论文
共 50 条
  • [1] PD-L1 expression and genotype in Non-Small Cell Lung Cancer (NSCLC)
    Ansen, S.
    Schultheis, A.
    Hellmich, M.
    Leenders, F.
    Zander, T.
    Michels, S.
    Brockmann, M.
    Stoelben, E.
    Groen, H.
    Timens, W.
    Buettner, R.
    Thomas, R. K.
    Perner, S.
    Wolf, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 5 - 6
  • [2] PD-L1 expression and genotype in non-small cell lung cancer (NSCLC).
    Ansen, Sascha
    Schultheis, Anne Maria
    Hellmich, Martin
    Zander, Thomas
    Brockmann, Michael
    Stoelben, Erich
    Groen, Harry J. M.
    Timens, Wim
    Buettner, Reinhard
    Thomas, Roman K.
    Perner, Sven
    Wolf, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Evaluation of the prognostic marker of PD-L1 expression after combined radio-chemotherapy in patients with non-small cell lung cancer (NSCLC) stage III
    Willborn, K.
    Wagner, J.
    Roeper, J.
    Falk, M.
    Heukamp, L. C.
    Griesinger, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S989 - S989
  • [4] Efficacy of Chemo-Radiotherapy (CRT) in Stage III Non-Small Cell Lung Cancer (NSCLC) and PD-L1 Expression
    Adam, Julien
    Boros, Angela
    Lacas, Benjamin
    Lacroix, Ludovic
    Pignon, Jean-Pierre
    Caramella, Caroline
    Planchard, David
    Levy, Antonin
    Besse, Benjamin
    Le Pechoux, Cecile
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S244 - S244
  • [5] Postoperative survivin expression in stage III non-small cell lung cancer (NSCLC) patients treated with neoadjuvant chemoradiation
    Fidler, M. J.
    Basu, S.
    Kaiser-Walters, K. A.
    Hadziahmetovic, E.
    Batus, M.
    Steker, D.
    Coon, J.
    Bonomi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] PD-L1 expression, EGFR and KRAS mutations in unresectable stage III non-small cell lung cancer (NSCLC) patients
    Cronin-Fenton, Deirdre
    Dalvi, Tapashi
    Hedgeman, Elizabeth
    Norgaard, Mette
    Pedersen, Lars
    Hansen, Hanh
    Fryzek, Jon
    Walker, Jill
    Mellemgaard, Anders
    Rasmussen, Torben
    Shire, Norah
    Riggas, James
    Potter, Danielle
    Hamilton-Dutoit, Stephen
    Sorensen, Henrik
    CANCER RESEARCH, 2018, 78 (13)
  • [7] Evaluation of the prognostic marker of PD-L1 expression after combined radiochemotherapy in patients with non-small cell lung cancer (NSCLC) stage III
    Wagner, Jan
    Roeper, Julia
    Willborn, Kay
    Griesinger, Frank
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 159 - 159
  • [8] Effect of neoadjuvant chemoimmunotherapy on PD-L1 expression in non-small cell lung cancer
    Stoykova, S.
    Chriqui, L.
    Berchtold, E. Abdelnour
    Peters, S.
    Perentes, J. Y.
    Berezowska, S.
    VIRCHOWS ARCHIV, 2024, 485 : S20 - S20
  • [9] Association of PD-L1 expression with hotspot mutations in non-small cell lung cancer (NSCLC).
    Wan, Renping
    Zhang, Xiaoni
    Qu, Hongyue
    Li, Hui
    Li, Yingmei
    Xu, Mingyan
    Xiao, Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] PD-L1 expression and survival in patients with non-small cell lung cancer (NSCLC) in Korea
    Sun, Jong-Mu
    Zhou, Wei
    Choi, Yoon-La
    Choi, So-Jung
    Kim, Se Eun
    Wang, Zhen
    Dolled-Filhart, Marisa
    Emancipator, Kenneth
    Weiner, Russell
    Park, Minjin
    Kim, Hong Kwan
    Choi, Yong Soo
    Shim, Young Mog
    Kim, Jhingook
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345